Melanoma Trial Landscape (June 2026)

Last updated: Jun 9, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Recently Updated Trials

NCT	Phase	Title	Mechanism
NCT02621021	2	A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab	Tumor infiltrating lymphocytes (TIL) -- adoptive cell therapy + IL-2 -- cytokine + PD-1 -- immune checkpoint inhibitor (pembrolizumab)
NCT06585410	3	Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma	PD-1 -- immune checkpoint inhibitor (monoclonal antibody)
NCT07631325	1, 2	Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma	Opioid receptors -- antagonist (small molecule)
NCT07634380	1	Sitagliptin With Pembro in RCC and Melanoma	DPP-4 -- enzyme inhibitor (small molecule)
NCT05136196	2	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study	Multiple kinases -- multi-kinase inhibitor (Cabozantinib); PD-1 -- immune checkpoint inhibitor (Nivolumab)

Top Sponsors

Sponsor	Recruiting trials
M.D. Anderson Cancer Center	18
H. Lee Moffitt Cancer Center and Research Institute	8
Vastra Gotaland Region	7
National Cancer Institute (NCI)	7
Xijing Hospital	5

Geographic Distribution

Countries/regions with the most active trial sites for melanoma. A multi-site trial is counted once per country/region.

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

Start	NCT	Title	Mechanism
Aug 31, 2026	NCT07444606	Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases	Oncolytic adenovirus -- oncolytic viral therapy (DNX-2401)
Aug 31, 2026	NCT07414979	Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma	Tumor antigens -- adoptive CD8+ antigen-specific T cell therapy
Aug 1, 2026	NCT07581509	Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma	PD-1 -- immune checkpoint inhibition (monoclonal antibody)
Jul 31, 2026	NCT07631325	Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma	Opioid receptors -- antagonist (small molecule)
Jul 2026	NCT07615881	Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma	CTLA-4 + PD-1 -- immune checkpoint blockade (monoclonal antibodies)
Jun 30, 2026	NCT07518043	A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors	PD-1 -- immune checkpoint inhibitor biosimilar (monoclonal antibody)
Jun 19, 2026	NCT07475572	A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma	PD-1 -- immune checkpoint inhibitor (monoclonal antibody biosimilar)
Jun 1, 2026	NCT07476326	Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma	PD-1 -- immune checkpoint inhibitor (nivolumab biosimilar Bmab1700 and Opdivo)

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.